Randomized trial comparing pegylated interferon α-2b versus pegylated interferon α-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

Abstract

. At baseline, both groups were well balanced: 73% male; 63% HCV genotype 1 through 4; 29% had fibrosis index of 3 or greater. The overall SVR was 44% (42% PEG 2b versus 46% PEG 2a, P ‫؍‬ 0.65). Among genotypes 1 through 4, SVRs were 28% versus 32% (P ‫؍‬ 0.67) and 62% versus 71% (P ‫؍‬ 0.6) in genotypes 2 through 3 for PEG 2b and PEG 2a, respectively. Early virological response (EVR; >2 log reduction from baseline or negative HCV-RNA at week 12) was 70% in the PEG 2b group and 80% in the PEG 2a group (P ‫؍‬ 0.13), reaching a positive predictive value of SVR of 64% and a negative predictive value of 100% in both arms. Side effects were present in 96% of patients but led to treatment discontinuation in 10% of patients (8% on PEG 2b and 13% on PEG 2a, P ‫؍‬ 0.47). Conclusion: In patients with HIV, HCV therapy with PEG 2b or PEG 2a plus RBV had no significant differences in efficacy and safety. (HEPATOLOGY 2009;49:22-310.)

Study of the Efficacy of Triple Therapy of Sofosbuvir, Pegylated INFalpha 2a and Ribavirin in Treatment of Chronic Hepatitis C Patients Genotype 4 with High Fibrosis

“…This goes with our paper as regard flu like symptoms and leucopenia but percentage of anemia was higher in our study [8].…”

“…In Montserrat et al 2009 stage of fibrosis was not related to response to treatment which doesn't coincide with ours [8].…”

Evaluation of the therapeutic response of hepatitis C in coinfected patients (HIV/HCV): a study of cases from a hospital for chronic liver diseases in the Eastern Brazilian Amazon

“…The biochemical response in HCV-HIV co-infected patients is not a good marker of SVR. In the, APRICOT (Aids Pegasys Ribavirin International Coinfection Trial), RIBAVIC, LAGUNO and PRESCO studies studies [16][17][18][19] , patients were using the HAART scheme in more than 70% of the cases, the mean CD4+ lymphocyte counts were above 500 cells/mm 3 and the ALT levels were normal in only 16% of cases in the RIBAVIC study. In the RIBAVIC (Ribavirin Study Team (France) and PRESCO studies, the stages of fibrosis were measured by the METAVIR classification (F3/F4) and were reported in 28 and 39% of cases, respectively.…”

The Role of Liver Transplantation in HIV Positive Patients

“…At present pegylated interferon and ribavirin are the only licensed medications for the treatment of HCV in HIV/HCV co-infected patients. Compared to HCV mono-infected patients, end-of-treatment (29-62%) and sustained virological response rates (SVR) are inferior (17-35%) (21)(22)(23)(24)(25)(26). The use of the newer protease inhibitors in the treatment of HCV in HIV-positive patients has only been limited to the trial arena.…”